Aspire Biopharma Holdings Inc. has entered into Exchange Agreements with certain holders of its debt to convert approximately $1.75 million in outstanding debt into shares of the company's common stock. The debt originated from agreements made by the company's predecessor, PowerUp Acquisition Corp., in early 2024. The transaction involves accredited investors and relies on exemptions from registration under the Securities Act. Additionally, the agreements provide that, upon future financings exceeding $3 million, holders may elect to receive a portion of the proceeds in cash to repay outstanding balances.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000518), on January 06, 2026, and is solely responsible for the information contained therein.
Comments